Disclosed is the use of a 2-phenyl-4-oxo-3,4-dihydroquinazoline derivative of Formula III, or a stereoisomer, tautomer, pharmaceutically acceptable salt, or hydrate thereof, in the preparation of a medicament for treating and/or preventing cancer characterized by altered expression of IL-6 or VCAM-1 in a subject (such as multiple myeloma, lymphoma, leukemia, solid tumors, prostate and bladder cancers, cardiac myxoma, tumor-induced cachexia, cerebral edema secondary to brain tumors, hormone-independent prostate cancer, B cell lymphoma, AIDS associated lymphoma, and metastatic renal cell carcinoma)； wherein: Q is CR12； V is nitrogen； U is C=O； X is selected from oxygen, sulfur, NH, and CR6R7； Z is selected from unsubstituted alkyl and alkyl substituted with one or more groups selected from alkyl, alkoxy, cyclopropyl, hydroxyl, amino, and halogen； n is 0, 1, 2, 3, 4, or 5； G is selected from heterocycle optionally substituted by one or more groups selected from oxo, phenyl, methyl, ethyl, isopropyl, acetyl, C(O)NMe2, NHC(O)Me, N(i-Pr)C(O)Me, and NH(i-Pr), and/or optionally fused to phenyl； cycloalkyl； and aryl optionally substituted by one or more methyl； R1 is selected from hydrogen and alkyl； R6, R7, and R12 are independently selected from hydrogen, alkyl, cycloalkyl, heterocycle, alkoxy, and halogen； Rc is selected from hydrogen, alkyl, and cycloalkyl； Ra1, Ra2, and Ra3 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, halogen, amino, amide, hydroxyl, and heterocycle, wherein Ra1 and Ra2 and/or Ra2 and Ra3 may be connected to form a cycloalkyl or a heterocycle； Rb2 and Rb6 are independently selected from hydrogen, halogen, alkyl, cycloalkyl, alkenyl, hydroxyl, and amino； and Rb3 and Rb5 are independently selected from hydrogen, halogen, alkyl, cycloalkyl, alkoxy, hydroxyl, and amino； wherein amide is -NRaC(O)(Rb) or -C(O)NRbRc, wherein Ra, Rb and Rc are each independently selected from alkyl, alkenyl, alkynyl, aryl, arylalkyl, cy
